Neumirna Therapeutics (‘Neumirna’), an RNA-focused biotech company developing next-generation therapeutics for neurological disorders, is pleased to announce the first closing of its Series A funding round at €20M. The investment was co-led by new investors, Angelini Ventures and Invivo Partners, with significant participation from Neumirna’s seed investor, Innovestor’s Life Science Fund and other existing investors.

Press inquiries should be adressed to: